By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Akebia Therapeutics, Inc. 

9987 Carver Road
Suite 420
Cincinnati  Ohio  45242  U.S.A.
Phone: 513-618-0931 Fax: 513-618-0950


Company News
Akebia (AKBA) To Host Analyst And Investor Day On June 27, 2017 6/20/2017 6:03:10 AM
Akebia (AKBA) Prevails In Two Additional European Patent Disputes 6/5/2017 12:29:10 PM
Akebia (AKBA) Names Rita Jain, M.D. As Chief Medical Officer 5/25/2017 8:18:41 AM
Akebia (AKBA) Initiates Phase II FO2RWARD Study Of Vadadustat In Dialysis Patients With Anemia Related To Chronic Kidney Disease Hyporesponsive To Treatment With Erythropoiesis-Stimulating Agents 5/24/2017 7:26:35 AM
Akebia (AKBA) And Vifor Pharma Announce Exclusive License Agreement To Provide Vadadustat To Fresenius Medical Care In The U.S. Upon Vifor Pharma Approval 5/16/2017 7:45:59 AM
Akebia (AKBA), Vifor Pharma Strike $50 Million Exclusive Anemia Drug Pact 5/16/2017 6:01:46 AM
Akebia (AKBA) Announces First Quarter 2017 Financial Results 5/10/2017 7:13:07 AM
Akebia (AKBA) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 5/5/2017 6:31:53 AM
Why Akebia (AKBA), Even With Otsuka Pharma's Big Deal, May Need To Be Acquired 4/27/2017 7:07:32 AM
Otsuka Pharma Believes in Akebia (AKBA), Commits Another $865 Million to Expand Anemia Deal 4/26/2017 5:38:54 AM